The XBI has fallen below the $95 range, down over 40% from its peak a year ago. The largest healthcare conference (JP Morgan 2022), which took place last week, failed to deliver the M&A activity & sweeping collaborations that typically kick off biotech's New Year.
The biotech supply glut (which was discussed here) is expected to continue. If past trends…